Literature DB >> 32323890

Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.

John C Panetta1, Yiwei Liu1, Hope D Swanson1, Seth E Karol2, Ching-Hon Pui2, Hiroto Inaba2, Sima Jeha2, Mary V Relling1.   

Abstract

It is unclear if dosing intervals for Erwinase can be extended with intramuscular (i.m.) versus intravenous (i.v.) dosing. Children with acute lymphoblastic leukemia received Erwinase at 30 000-42 000 IU/m2 i.v. or i.m. I.m. Erwinase (n = 22) achieved activity above 0.1 IU/mL for longer than i.v. Erwinase (n = 33) (3.4 vs 2.9 days, P = 0.0007). With 30 000 IU/m2 Monday, Wednesday, Friday, more patients achieved adequate concentrations over the weekend with i.m. vs i.v. dosing (P = 5 × 10-36 ). A schedule with i.v. doses on Monday and Wednesday and i.m. doses on Friday of 30 000 IU/m2 maintained activity > 0.1 IU/mL over the weekend in 80% of patients.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Erwinase; acute lymphoblastic leukemia; asparaginase; intramuscular; intravenous; pharmacokinetics

Mesh：

Substances：

Year:  2020        PMID： 32323890      PMCID： PMC7253324          DOI： 10.1002/pbc.28244

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  15 in total

1.  Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.

Authors:  Marc Lavielle; Benjamin Ribba
Journal:  Pharm Res       Date:  2016-09-07       Impact factor: 4.200

2.  Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.

Authors:  Yiwei Liu; Colton A Smith; John C Panetta; Wenjian Yang; Lauren E Thompson; Jacob P Counts; Alejandro R Molinelli; Deqing Pei; Nancy M Kornegay; Kristine R Crews; Hope Swanson; Cheng Cheng; Seth E Karol; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling
Journal:  J Clin Oncol       Date:  2019-06-12       Impact factor: 44.544

3.  Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.

Authors:  J P Vieira Pinheiro; E Ahlke; U Nowak-Göttl; G Hempel; H J Müller; K Lümkemann; M Schrappe; B Rath; G Fleischhack; G Mann; J Boos
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

4.  Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration.

Authors:  B K Albertsen; P Jakobsen; H Schrøder; K Schmiegelow; N T Carlsen
Journal:  Cancer Chemother Pharmacol       Date:  2001-07       Impact factor: 3.333

Review 5.  L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Authors:  Rob Pieters; Stephen P Hunger; Joachim Boos; Carmelo Rizzari; Lewis Silverman; Andre Baruchel; Nicola Goekbuget; Martin Schrappe; Ching-Hon Pui
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

6.  L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.

Authors:  C Rizzari; M Zucchetti; V Conter; L Diomede; A Bruno; L Gavazzi; M Paganini; P Sparano; L Lo Nigro; M Aricò; M Milani; M D'Incalci
Journal:  Ann Oncol       Date:  2000-02       Impact factor: 32.976

7.  High-throughput asparaginase activity assay in serum of children with leukemia.

Authors:  Christian A Fernandez; Xiangjun Cai; Allie Elozory; Chengcheng Liu; J Carl Panetta; Sima Jeha; Alejandro R Molinelli; Mary V Relling
Journal:  Int J Clin Exp Med       Date:  2013-08-01

8.  Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

Authors:  Vassilios I Avramis; Sagrario Martin-Aragon; Earl V Avramis; Barbara L Asselin
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

9.  Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.

Authors:  Sima Jeha; Deqing Pei; John Choi; Cheng Cheng; John T Sandlund; Elaine Coustan-Smith; Dario Campana; Hiroto Inaba; Jeffrey E Rubnitz; Raul C Ribeiro; Tanja A Gruber; Susana C Raimondi; Raja B Khan; Jun J Yang; Charles G Mullighan; James R Downing; William E Evans; Mary V Relling; Ching-Hon Pui
Journal:  J Clin Oncol       Date:  2019-10-28       Impact factor: 44.544

10.  Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.

Authors:  Sebastiaan D T Sassen; Ron A A Mathôt; Rob Pieters; Robin Q H Kloos; Valérie de Haas; Gertjan J L Kaspers; Cor van den Bos; Wim J E Tissing; Maroeska Te Loo; Marc B Bierings; Wouter J W Kollen; Christian M Zwaan; Inge M van der Sluis
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941
View more
  2 in total

1.  Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia.

Authors:  Randal K Buddington; Karyl K Buddington; Scott C Howard
Journal:  Med Sci (Basel)       Date:  2022-08-12

2.  Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.

Authors:  John C Panetta; Yiwei Liu; Teodoro Bottiglieri; Erland Arning; Cheng Cheng; Seth E Karol; Jun J Yang; Yinmei Zhou; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-25       Impact factor: 3.288
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.